ANI Pharmaceuticals’ (ANIP) “Buy” Rating Reiterated at Guggenheim

ANI Pharmaceuticals (NASDAQ:ANIP)‘s stock had its “buy” rating reaffirmed by equities researchers at Guggenheim in a research note issued on Friday,Benzinga reports. They presently have a $124.00 price objective on the specialty pharmaceutical company’s stock. Guggenheim’s target price suggests a potential upside of 48.01% from the stock’s previous close.

A number of other analysts have also issued reports on ANIP. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Finally, Weiss Ratings raised ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

ANI Pharmaceuticals Trading Down 1.2%

Shares of ANIP opened at $83.78 on Friday. ANI Pharmaceuticals has a 1-year low of $62.60 and a 1-year high of $99.50. The company has a 50-day moving average of $81.50 and a 200 day moving average of $79.49. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of 21.21 and a beta of 0.43. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.77. The company had revenue of $237.46 million during the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm’s quarterly revenue was up 20.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, research analysts expect that ANI Pharmaceuticals will post 8.03 EPS for the current year.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 2,772 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $79.50, for a total transaction of $220,374.00. Following the transaction, the senior vice president owned 78,696 shares of the company’s stock, valued at approximately $6,256,332. This trade represents a 3.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Patrick D. Walsh sold 10,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $80.63, for a total transaction of $806,300.00. Following the completion of the sale, the director owned 38,432 shares of the company’s stock, valued at approximately $3,098,772.16. This represents a 20.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 85,179 shares of company stock worth $6,720,651 over the last quarter. Corporate insiders own 8.10% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of large investors have recently bought and sold shares of ANIP. Pacer Advisors Inc. lifted its holdings in ANI Pharmaceuticals by 6.9% during the first quarter. Pacer Advisors Inc. now owns 85,467 shares of the specialty pharmaceutical company’s stock worth $6,572,000 after buying an additional 5,548 shares during the period. Bank of America Corp DE boosted its position in ANI Pharmaceuticals by 229.4% during the 1st quarter. Bank of America Corp DE now owns 150,532 shares of the specialty pharmaceutical company’s stock valued at $11,576,000 after acquiring an additional 104,828 shares in the last quarter. Janus Henderson Group PLC boosted its position in ANI Pharmaceuticals by 1,308.1% during the 1st quarter. Janus Henderson Group PLC now owns 109,552 shares of the specialty pharmaceutical company’s stock valued at $8,425,000 after acquiring an additional 101,772 shares in the last quarter. California State Teachers Retirement System increased its holdings in shares of ANI Pharmaceuticals by 57.3% in the 1st quarter. California State Teachers Retirement System now owns 24,557 shares of the specialty pharmaceutical company’s stock valued at $1,888,000 after acquiring an additional 8,946 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of ANI Pharmaceuticals by 1.5% in the 1st quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock valued at $736,000 after acquiring an additional 143 shares during the period. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.